Abstract
Abstract
After Covid-19 infection, 12.5% develop a post-Covid-syndrome. Symptoms affect numerous organ systems, but after one year they are mainly neurological and neuropsychiatric in nature. There is evidence that treatment with selective serotonin reuptake inhibitors (SSRIs) during Covid-19 infection decreases the likelihood of a post-Covid condition, but there is no known research on treating post-Covid syndrome itself with SSRIs. This study used an exploratory questionnaire and found that 63,4% of 95 post-Covid syndrome patients reported a reasonably good to strong response to an SSRI. Outcomes were measured with three different measures that correlated strongly with each other. Brainfog and sensory overload decreased the most. Patients experienced improved well-being. The response to SSRIs in post-Covid conditions was explained by seven possible neurobiological mechanisms as reported in the recent literature. The promising results of this study should be followed by a randomized controlled trial.
Publisher
Research Square Platform LLC
Reference49 articles.
1. Long COVID: major findings, mechanisms and recommendations;Davis HE;Nat Rev Microbiol,2023
2. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 30 March 2023;Office for National Statistics,2023
3. Fogoros, R. N. What Is Tilt Table Testing? What to expect when undergoing this test. https://www.verywellhealth.com/tilt-table-testing-1745418 (2022).
4. Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID;Oaklander AL;Neurology - Neuroimmunology Neuroinflammation,2022
5. A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity;Kedor C;Nat Commun,2022